MT. KISCO, N.Y., Dec. 07, 2016 -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today announced that a Definitive Agreement has been reached with Dr. Lilliana Ramirez to endorse and assist with the development of a new line of skincare products based on Immudyne’s proprietary Yeast Beta Glucan ingredient. The brand, Inate MD, will be launched nationally January 1, 2017.
Dr. Lilliana Ramirez is a practicing, board certified dermatologist with a distinguished track record in medicine and academics. She graduated Magna Cum Laude from the University of Puerto Rico and has received many awards for both her research and the practice of medicine.
“Immudyne is partnering with and associating our brand with yet another highly accomplished dermatologist,” stated Mark McLaughlin, President and CEO of Immudyne.
“I’m very pleased to be working with Immudyne,” said Dr. Ramirez. "The Inate MD skincare line is backed by excellent science and a great management team. I think my patients and consumers across the county will enjoy and benefit from use of the Inate MD product line.”
The Inate MD line will initially be available exclusively online and will consist of a Serum, Moisturizer, Instant Wrinkle Eraser and an optional nutritional supplement to support healthier skin and the human Immune System.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which are, in some cases, beyond the control of Immudyne. Actual events, performance or results could differ materially from the anticipated events, performance or results expressed or implied by such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
About ImmuDyne, Inc.
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. ImmuDyne also has a majority owned direct marketing division that markets immune support, skincare and hair loss products directly to consumers around the world. All of the Company’s intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Contact: lmmuDyne, Inc. Mark McLaughlin: +1-914-714-8901


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Washington Post Publisher Will Lewis Steps Down After Layoffs 



